UK markets closed

Baudax Bio, Inc. (BXRXQ)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.0080+0.0021 (+35.59%)
At close: 02:51PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 422.85k
Enterprise value 8.16M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.03
Price/book (mrq)N/A
Enterprise value/revenue 6.43
Enterprise value/EBITDA -0.17

Trading information

Stock price history

Beta (5Y monthly) 1.50
52-week change 3-56.74%
S&P500 52-week change 323.76%
52-week high 30.0240
52-week low 30.0026
50-day moving average 30.0099
200-day moving average 30.0125

Share statistics

Avg vol (3-month) 365.07k
Avg vol (10-day) 367.32k
Shares outstanding 543.59M
Implied shares outstanding 643.59M
Float 843.59M
% held by insiders 10.02%
% held by institutions 12.68%
Shares short (31 Oct 2023) 4474.29k
Short ratio (31 Oct 2023) 40.19
Short % of float (31 Oct 2023) 43.90%
Short % of shares outstanding (31 Oct 2023) 43.90%
Shares short (prior month 29 Sept 2023) 435.68k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,759.89%

Management effectiveness

Return on assets (ttm)-114.93%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)1.27M
Revenue per share (ttm)0.32
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -34.76M
Net income avi to common (ttm)-59.2M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)363k
Total cash per share (mrq)0.01
Total debt (mrq)8.1M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.07
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-14.31M
Levered free cash flow (ttm)-15.93M